Hemab Therapeutics Holdings, a Phase 3-ready biotech developing blood coagulation disorder treatments, raised $302 million by offering 16.8 million shares at $18, the high end of the $16 to $18 range. The company originally filed to offer 11.8 million shares at the same range, before it increased the proposed share offering on Thursday morning. At pricing, Hemab raised just over 50% more in proceeds than originally planned.
Hemab is a clinical-stage biotechnology company developing antibody-based therapies for inherited bleeding and coagulation disorders. Its lead candidate, sutacimig (HMB-001), finished Phase 2 and is ready for Phase 3 for Glanzmann thrombasthenia and Phase 2 for Factor VII deficiency, while HMB-002 is in Phase 1/2 for Von Willebrand Disease. The company’s programs are focused on prophylactic subcutaneous treatments for rare disorders with limited existing options, and it is also advancing additional preclinical candidates in coagulation-related diseases.
The Cambridge, MA-based company will trade on the Nasdaq under the symbol COAG. Goldman Sachs, Jefferies, and Evercore ISI acted as joint bookrunners on the deal.
